Kornimate/medical-research-clean huggingface dataset:
evaluating serum sestrin in leiomyoma patients

Conditions: Uterine Leiomyoma

Summary: leiomyomas are the most common benign neoplasms of women's reproductive system affecting 20-30% of women within the reproductive ages. sestrins are serum proteins which are highly expressed under circumstances of dna damage, hypoxia and oxditive stress and play an important role in autophagia. the aim of this study is to evaluate the relationship of serum sestrin proteins with development of leiomyomas.

leiomyomas are the benign neoplasms of uterus and the role of genetics, estrogen levels and obesity has already been shown in their development. higher levels of serum sestrin proteins have already been associated with dna damage, hypoxia and oxidative stress and sestrin plays an important role in autophagia. in order to evaluate the role of serum sestrin in the development of leiomyomas 30 patients between 18-45 years of age who were diagnosed with uterine leiomyomas with transvaginal ultrasonography will be included in the study group. their serum sestrin levels will be determined and compared with that of 30 healthy subjects recruited during the same study period at the same clinic.

Eligibility criteria:
inclusion criteria: * 18-45 years of age * patients diagnosed with uterine leiomyomas will be included in the study group * patients without any additional comorbidities * patients without any autoimmune diseases exclusion criteria: * patients with systemic diseases * patients with known chronic inflammatory diseases * patients using hormonal and/or medical therapy * pregnant women * lactating women * patients with malignant diseases
elastic abdominal binder following gynecologic cancer surgery

Conditions: Gynecologic Cancer

Summary: surgery is the primary treatment for gynecologic malignancies. the surgical approach provides opportunities for removal of the affected organs and complete assessment of extent of cancer spread. however, the procedures are often associated with significant morbidity. this is especially true with open laparotomy, the most frequently employed approach in developing countries. delayed functional recovery influenced by pain and immobilization are important contributing factors for increased morbidity. elastic abdominal binder, a wide elastic belt that is wore around the patient's abdomen to support surgical incision after surgery, has been employed by clinicians for pain relief, wound complications prevention, improved pulmonary function, and stabilization. benefits of the abdominal binder use in this patient population have not been properly examined. the aim of this study is to examine the effect of postoperative elastic abdominal binder use on recovery by comparing pain scores and mobility function (through the 6-minute walk test \[6mwt\]) in postoperative gynecologic cancer patients who use versus do not use the elastic abdominal binder to support incisional site.


Eligibility criteria:
inclusion criteria: * women, diagnosed with gynecologic malignancies (carcinoma of the cervix, endometrium, and ovary), undergoing open abdominal surgery exclusion criteria: * intraoperative accidental injury to urinary or gastrointestinal organs * postoperative admission to intensive care unit (icu) * postoperative intraperitoneal drain placement * unable to understand and follow oral/written instructions * severe neuromuscular or circulatory disorders
spinal cord stimulation for refractory pain in erythromelalgia

Conditions: Erythromelalgia

Summary: erythromelalgia is a rare disorder characterized by red, warm, and painful extremities, which is often precipitated by warm conditions. the pathophysiology is incompletely understood. the management of pain in erythromelalgia is challenging as no single therapy has been found to be effective. response to pharmacotherapy varies, meaning that the physician has to take a stepwise trial and error approach with each patient. consequently, this disorder is often associated with poorer health-related quality of life. there is currently no consensus or guideline on management of pain in erythromelalgia. spinal cord stimulation is a widely applied therapy to treat severe chronic pain of various origin. case reports and anecdotal evidence suggest that this therapy might alleviate refractory pain in patients with erythromelalgia. the aim of this trial is to evaluate the efficacy of spinal cord stimulation for refractory pain in erythromelalgia.


Eligibility criteria:
inclusion criteria: 1. a diagnosis of primary or idiopathic erythromelalgia 2. patients ≥18 years who have developed chronic pain that has remained refractory to medical treatment for ≥6 months. 3. minimum pain intensity of 5/10 on a numeric rating scale nrs at baseline. 4. successful two-week scs testing period with tonic stimulation (≥2 points reduction in pain nrs from baseline). this means patients will experience paresthesia during the trial period of spinal cord stimulation. exclusion criteria: 1. coexisting conditions that would increase procedural risk (e.g., sepsis, coagulopathy). 2. history of laminectomy or posterior fusion at the thoracolumbar junction, where percutaneous electrode end tips are routinely placed. 3. abnormal pain behavior and/or unresolved psychiatric illness. 4. unresolved issues of secondary gain or inappropriate medication use. 5. unfit for participation for any other reason as judged by the study physician.

Keywords: spinal cord stimulation
incontinence management system icu field evaluation

Conditions: Urinary Incontinence; Fecal Incontinence

Summary: the objective of this field evaluation is to assess usage and satisfaction associated with the hill-rom incontinence management system.


Eligibility criteria:
inclusion criteria: * patients with urinary, fecal, or dual incontinence who are ≥ 18 years old * the patient, or the patient's legal authorized representative (lar), is willing and able to provide written informed consent exclusion criteria: - patients that are considered to be near death or require palliative care
comparison 1 plane-1 injection and 2 plane-2 injection ultrasound-guided supraclavicular brachial plexus block

Conditions: Radius Fractures

Summary: ultrasound-guided supraclavicular brachial plexus block (us-scbpb) has been a generalized regional anesthesia in upper extremity surgery. it is performed just above the clavicle, in which the neural cluster formed by the trunks or divisions of the brachial plexus is situated superolateral to the subclavian artery (sa). in many approaches, corner pocket approach \[deposit local anesthetic (la) at the intersection of the sa, neural cluster, and the first rib\] and cluster approach (direct deposit la into the neural cluster after penetration of the sheath of brachial plexus) has been well known methods. and single or multiple injection techniques has been used with the above approaches.

in clinical practices, the investigators observed that the neural cluster was shown differently every person on the ultrasound image. some neural cluster is shown as a typical round cluster of grapes lateral to the sa, in which, any approaches of us-scbpb can be possible and good success rates are anticipated. but in many cases, neural cluster was shown in part lateral or superolateral to the sa like slightly-hated sa on the ultrasound image, and it passes posterior to the sa when the probe follows the path of the neural cluster along the sa. in that case, corner pocket approach is hard to apply due to the position of the neural cluster far away from the first rib, cluster approach increases chance of lopsided spreading of the la, and multiple injection is also hard to apply due to narrow-shaped neural cluster. therefore, we hypothesized that double injection in different plane (we call this new approach as a 2 plane-2 injection approach) would achieve an effect of a "tridimensionally administered la", which is presented like shortening the onset time or increasing rate of all four nerves block compared with the existing cluster approach (the investigators call this as an 1 plane- 1 injection approach in this study).

Eligibility criteria:
inclusion criteria: * all patients anticipating surgery of the wrist or hand with aged 18 to 80 years and an american society of anesthesiologists physical status (asa) of i or ii. exclusion criteria: * patients with preexisting neuropathy in the operated limb, asa greater than iii, coagulation disorders, known allergy to local anesthetics, local infection at the puncture site, chronic obstructive pulmonary disease or respiratory failure, pregnancy, breast-feeding and prior surgery in the supraclavicular region, bmi ≥ 35 kg/㎡, uncooperative patients and patients' refusal. an ultrasound view of the perfect circular neural cluster.

Keywords: brachial plexus block nerve stimulator ultrasound
the saeboglove evaluation trial

Conditions: Stroke; Cerebral Vascular Disorder; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Summary: this study evaluates the safety, feasibility and usability of a saeboglove rehabilitation device in the treatment of patients who have reduced ability to open their hand due to weakness after an acute stroke.

the saeboglove is a new rehabilitation aid that can be used in people with hand weakness after a neurological injury. it assists the hand to open, which is crucial for people to grasp, and release everyday objects. it may improve function by doing this but may also help people with severe weakness take part more fully in therapy sessions. this glove is already marketed and is being used in some nhs sites. this trial will assess how it could be used in nhs practice in acute stroke patients and will develop a plan to implement this.

Eligibility criteria:
inclusion criteria: 1. able to consent 2. aged ≥18 years 3. diagnosis of stroke occurring ≤30 days ago 4. reduced active range of movement wrist and / or finger extension 5. modified ashworth score at wrist and fingers ≤ 2 6. some initiation of gross active finger flexion 7. at least 10 degrees passive range of motion wrist extension 8. considered able to learn to don / doff a saeboglove +/- help of willing carer 9. ability to engage in some independent rehabilitation +/- help of willing carer 10. considered able to comply with the requirements of protocol? exclusion criteria: 1. presence of \>5-10 degrees digital contractures 2. presence of other upper limb impairment that would influence participation (e.g. fixed contracture, frozen shoulder, severe arthritis or upper limb pain) 3. presence of other conditions likely to influence participation (e.g. medically unstable, registered blind, terminal cancer, severe mood, cognitive or language issues) 4. participating in another stroke rehabilitation trial
a comparative clinical trial of the tensortip, a novel non invasive device for measurement blood parameters

Conditions: Anemia; Diabetes; Heart Disease; High Blood Pressure; Hypotension; Metabolic Diseases; Respiratory Diseases

Summary: 1. aim: the aim of the clinical trial is to study the accuracy of the tensortip device compared with registered (fda-approved) invasive and non-invasive devices. 2. hypothesis: human physiological biomarkers may be measured from the color distribution of the internal or external (skin) tissue. the technology of the tensortip finger-mounted device is based on the color distribution of the peripheral blood tissue, which enables the measurement of certain biomarkers and vital signs under consideration.

the tensortip (previously named soft touch) is a novel non invasive finger tip device that. the tensor tip is a non-invasive device which was designed and aimed to measure a wide range of physiological and bio-parameters such as blood glucose, hemoglobin and hematocrit, blood ph, oxygen saturation spo2, blood carbon dioxide, blood pressure, peripheral pulse and more based on the temporarily color distribution of the tissue under consideration. the tensor tip is based on real time color image sensor, real time photographing the fingertip tissue. a color image sensor of the type used in the tensor tip enables a wide range of information in the spectral, resolution, dynamic range and time domains enabling further investigation of the blood chromatic changes as a function body physiology. the concept behind this investigation reflects the idea that a change in human physiology condition would temporarily change the blood pigmentation. the present study is aimed to assess the accuracy of the novel device in measuring all the above mentioned parameters by recording as is the change of the fingertip color tissue while simultaneous recording the standard invasive measured parameters on daily or periodic routine in the hospitalized patients. this vast data recordings (tissue and references) enable the tensor tip to analyze a particular bio parameter. the tensor tip is calibrated to a certain bio parameter based on the vast data set collected. the bio parameter under consideration are: arterial systolic and diastolic, map, pa systolic, pa diastolic, co, heart rate, stroke volume, wbc, rbc, hgb, hct ,iron, plt, ph, pco2, po2, hco3, sao2 , na, k, cl, co2, bun, cr, gluc, hgb (a1c),tbili, ldl, hdl. this study hopes to demonstrate the connection between blood color pigmentation and certain bio parameters for simplifying monitoring procedure and particular home monitoring.

Eligibility criteria:
inclusion criteria: 1. male or female, age \> 18 2. patients with cardiovascular disease and/or with diabetes mellitus type i or ii and/or with copd. 3. patients receiving coronary artery bypass with or without valve repair. 4. able to sign an informed consent. exclusion criteria: 1. refusal to sign an informed consent and to participate in the study. 2. participant plans to enroll in another other clinical trial of an investigational agent while participating in this study. 3. below the age of 18.
a study in japanese participants with moderate-to-severe psoriasis

Conditions: Psoriasis

Summary: this study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in japan.


Eligibility criteria:
inclusion criteria: * men must agree to use a reliable method of birth control during the study * women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment * candidates for phototherapy and/or systemic therapy * present with chronic psoriasis based on a confirmed psoriasis diagnosis for at least 6 months prior to enrollment * at least 10% body surface area (bsa) of psoriasis at screening and at enrollment for participants with plaque psoriasis * static physician global assessment (spga) score of at least 3 and psoriasis area and severity index (pasi) score of at least 12 at screening and at enrollment for participants with plaque psoriasis exclusion criteria: * history of drug-induced psoriasis * concurrent or recent use of any biologic agent * received systemic psoriasis therapy \[such as psoralen and ultraviolet a (puva) light therapy\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment for participants with plaque psoriasis * cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study * have participated in any study with interleukin-17(il-17) antagonists, including ixekizumab * serious disorder or illness other than psoriasis * serious infection within the last 3 months * breastfeeding or nursing (lactating) women * clinically significant flare of psoriasis during the 12 weeks prior to enrollment for participants with plaque psoriasis
effects of home-based or center-based aerobic exercise in patients with chronic kidney disease

Conditions: Chronic Renal Failure; Obese

Summary: patients will be randomly assigned to perform the training program in center or home-based . the training program will be conducted in accordance with the recommendations of the american college of sports medicine. all training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). the program will consist of 24 weeks with three sessions per week on alternate days. the aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. the intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. the intensity control was done by means of the heart rate value obtained at ventilatory threshold. both groups receive the same intervention. however, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher. the other group will exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher. it will also constituted a control group remain without performing any activity during the study period. after 24 weeks patients receive the same advice the team conducting the training at home.


Eligibility criteria:
inclusion criteria: * sedentary individuals with chronic kidney disease stages 3 or 4 disease; * both genders; * age between 30 and 65 years; * overweight (bmi\> 25 kg/m2); * with a negative stress test. exclusion criteria: * patients with chronic obstructive pulmonary disease, * class iv heart failure, * myocardial infarction within the last 6 months, * decompensated hypertension (systolic blood pressure\> 180 mmhg or diastolic\> 110 mmhg in the last 6 months), * uncontrolled cardiac arrhythmia, * decompensated diabetes mellitus (glycated hemoglobin\> 8.0%), * unstable angina, * infectious processes in the last 3 weeks; * begin use of erythropoietin or with hemoglobin \<11g/l. * use of beta-blocker medication
trial comparing tack versus histoacryl mesh fixation after endoscopic tep(total extraperitoneal) repair for bilateral inguinal hernia

Conditions: Inguinal Hernia

Summary: this prospective randomized trial is performed to analyze the post-operative pain (acute and chronic) after endoscopic tep repair after bilateral inguinal hernia repair.

consecutive patients with bilateral inguinal hernias will be recruited for tep repair. mesh fixation methods spiral tacks glue is randomly assigned to one side to the groin and histoacryl synthetic glue to the other side. patients will be followed up regularly for up to 6 months by an independent clinical nurse was blinded to the mesh fixation assignment. the patients are also blinded to the the mesh fixation assignment. the post operative pain score, peri-operative complication, and recurrences will be documented.

Eligibility criteria:
inclusion criteria: * patients present with clinical bilateral inguinal hernias and feasible for general anesthesia exclusion criteria: * patient preference for either fixation technique, refusal to participate, previous major lower abdominal surgery, concomitant surgical procedures other than hernia repair, and history of allergy to histoacryl.
efficacy of rituximab for the treatment of calcineurin inhibitors dependent nephrotic syndrome during childhood

Conditions: Childhood Idiopathic Nephrotic Syndrome

Summary: background idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine). renal function of patients suffering from severe, steroid-dependent nephrotic syndrome with failure or toxic side effects of other immunosuppressant treatments is a major matter of concern. cyclosporine endangers renal parenchyma (fibrosis) in these patients who must take this treatment for years. at the same time, low doses of cyclosporine allow proteinuria to reappear, which provokes degradation of renal function by focal segmental glomerulosclerosis. some recent data lead to the conclusion that rituximab may be effective in such a disease, with a cyclosporin sparing effect. purpose the aim of the study is to evaluate the efficacy of rituximab versus placebo in the treatment of pediatric patients suffering from severe cyclosporine-dependent nephrotic syndrome. abstract patients will be included in the study in a period of remission of proteinuria. two infusions of rituximab - at the dose of 375 mg/m²- or placebo will be administered at one week of interval. other immunosuppressant treatments will be gradually tapered off with the same tapering pattern in both groups. in case of relapse of nephrotic syndrome, the blinding code will be broken. rituximab will then be infused to patients having received placebo.

after infusions of rituximab or placebo, patients will be examined by their nephrologist on a monthly basis during five months. follow up will be focused on proteinuria, albuminemia, lymphocyte phenotyping and rituximab pharmacokinetics

Eligibility criteria:
inclusion criteria: * male or female patients over 2 and under 18 years, with an idiopathic nephrotic syndrome (ns) * steroid sensitive nephrotic syndrome (according to the french pediatric protocol). nephrutix * calcineurin inhibitor dependent ns or ns for which anticalcineurin treatment has not been effective. others immunosuppressive treatments (mmf) must have failed to control the disease activity. * effective contraception for girls of childbearing age. * the patient is able to understand and has signed a written informed consent or the parent or legal guardian is able to understand and has signed a written informed consent, which must be obtained prior to the initiation of any study procedure exclusion criteria: * terminal renal failure requiring dialysis/transplantation * transcutaneous oxygen stauration \< 97% * clinical or radiological brochopulmonar or pleural abnormality * asymptomatic carrier of hepatitis b virus our history of hepatitis b * contraindication to rituximab (rtx) * parents/patient refusing to participate in the study

Keywords: rituximab idiopathic nephrotic syndrome minimal change disease focal and segmental glomerulosclerosis
an open-label, randomized, phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage iv or recurrent pd-l1+ non-small cell lung cancer (checkmate 026)

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer

Summary: the purpose of this study is to show that nivolumab will improve progression free survival in subjects with strongly stage iv or recurrent pd-l1+ non-small cell lung cancer when compared to chemotherapy


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status (ps) ≤ 1 * histologically confirmed stage iv, or recurrent nsclc with no prior systemic anticancer therapy * measurable disease by computed tomography (ct) or magnetic resonance imaging (mri) per response evaluation criteria in solid tumors version (recist) 1.1 criteria * pd-l1+ on immunohistochemistry testing performed by central lab * men and women, ages ≥ 18 years of age exclusion criteria: * known epidermal growth factor receptor (egfr) mutations which are sensitive to available targeted inhibitor therapy * known anaplastic lymphoma kinase (alk) translocations * untreated central nervous system (cns) metastases * previous malignancies * active, known or suspected autoimmune disease